Published in 2016 in the Stanford Social Innovation Review, this article discusses the highly effective volume guarantees supplied to two major pharmaceutical firms in 2012 by the Bill and Melinda Gates Foundation (BMGF) and other funders.
The guarantees were put in place to roughly double the supply and halve the price of contraceptive implants – the results have since surpassed expectations. In the first three years of the guarantees the annual run rate more than doubled from 4.7 to almost 10 million, and price reductions saved more than $240 million for global public health donors.
The article emphasises that even with lower prices, higher volumes can drive bigger profits—a classic win-win for both consumers and producers.
Read: SSIR’S GUARANTEED IMPACT
Gavi, MedAccess and GlaxoSmithKline join forces to guarantee continued production of the RTS,S antigen for the RTS,S/AS01e malaria vaccine ahead of key policy and funding decisions.
MedAccess CEO Michael Anderson joined Laura Frigenti and Simba Makoni to discuss trends in financing for global health and how the COVID-19 pandemic has affected funding.
Extension will support UNICEF's work to accelerate access to essential supplies for countries around the world